ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2309

A Novel Approach to Assess Wait-Times to Rheumatologists

Jessica Widdifield1, Claire Bombardier2, J. Carter Thorne3, R. Liisa Jaakkimainen4, J. Michael Paterson1, Sasha Bernatsky5, Jacqueline Young1, Laura Wing1, Noah Ivers6, Debra Butt1, Vivian Poon1, Vandana Ahluwalia7 and Karen Tu1, 1Institute for Clinical Evaluative Sciences, Toronto, ON, Canada, 2Rheumatology, University of Toronto, Toronto, ON, Canada, 3Southlake Regional Health Centre, Newmarket, Newmarket, ON, Canada, 4Sunnybrook Health Sciences Centre, Toronto, ON, Canada, 5Divisions of Rheumatology and Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, 6University of Toronto, Toronto, ON, Canada, 7William Osler Health Center, Brampton, ON, Canada

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Access to care and inflammatory arthritis

  • Tweet
  • Email
  • Print
Session Information

Title: Quality Measures and Quality of Care

Session Type: Abstract Submissions (ACR)

Background/Purpose: Previous studies quantifying delays in assessment of patients by rheumatologists have studied patients from rheumatology clinics and thus include all patients who ultimately had access to rheumatologists. Our study estimates overall wait times for initial rheumatology consultations for patients referred by their primary care physician.

Methods: We employed a novel approach to identify first-time rheumatology referrals from the primary care Electronic Medical Record Administrative data Linked Database (EMRALD), representing comprehensive EMR data from 168 primary care physicians across Ontario, Canada (32 rural, 39 suburban and 97 urban physicians). We randomly sampled patients with rheumatology referral letters and performed linkage with administrative data to retrospectively confirm that patients had no prior rheumatologist assessments. Using a standardized data abstraction tool, the entire patient medical record was reviewed to categorize each patient according to their diagnosis: systemic inflammatory conditions, mechanical/degenerative/arthritic conditions, chronic pain, regional musculoskeletal (MSK) syndromes, osteoporosis/osteopathies, and other (e.g., abnormal diagnostic tests). Administrative data were then used to identify the date of the first rheumatologist visit subsequent to the date recorded on the referral identified in the EMR. The time in days from the date the first referral letter was sent to the date of the first rheumatologist visit was determined overall and for each diagnostic category.

Results: Among 1086 patients with first-time referrals, 99% of referrals analyzed occurred between 2006 and 2013. The majority of referrals were for mechanical/degenerative conditions (34%) and systemic inflammatory conditions (30%). Overall, 36% of patients were seen by a rheumatologist within 6 weeks from referral and 67% within 3 months. 68 (6%) patients were waiting longer than 12 months to be seen (Table). The average wait time to see a rheumatologist for any condition was 142 days (median 61) post-referral. For patients with systemic inflammatory conditions, the median time to be seen was 47 days (interquartile range 18-97). The median wait times for individuals with conditions deemed non-urgent (osteoarthritis, chronic pain) were roughly 2 weeks longer.

Conclusion: Using EMRs from a representative sample of Ontario primary care practices revealed longer wait times to see a rheumatologist than previous Canadian reports that sampled patients from urban rheumatology clinics. 33% of patients were still waiting >3 months to be seen, exceeding current Canadian recommendations. Individuals with systemic inflammatory conditions were seen earlier compared to other types of referrals. An analysis of wait times along each component of the care pathway is currently underway.


Overall

N = 1086

Systemic Inflammatory Conditions

n = 321

(30%)

Mechanical/

Degenerative/

Arthritic Conditions

n = 370

(34%)

Regional MSK Syndromes

n = 181 (17%)

Chronic Pain Conditions

n = 134 (12%)

Osteoporosis/

Osteopathies

n = 16

(2%)

Other

n = 64

(6%)

Age at Time of referral, mean (SD) years

54 (16)

55 (16)

57 (15)

53 (15)

48 (14)

50 (19)

46 (16)

Female, n (%)

734 (68%)

173 (54%)

256 (69%)

127 (70%)

116 (87%)

15 (94%)

47 (73%)

Seen by a rheumatologist within <6 weeks, n (%)

391 (36%)

153 (48%)

102 (28%)

71 (39%)

40 (30%)

< 5

21 (33%)

Seen by a rheumatologist between 6 weeks to 3 months, n (%)

331 (31%)

83 (26%)

127 (34%)

56 (31%)

42 (31%)

< 5

20 (31%)

Seen by a rheumatologist between 3 to 6 months, n (%)

214 (20%)

45 (14%)

87 (24%)

31 (17%)

28 (21%)

7 (44%)

16 (25%)

Seen by a rheumatologist between 6 to 9 months, n (%)

56 (5%)

16 (5%)

20 (5%)

5 (3%)

11 (8%)

< 5

< 5

Seen by a rheumatologist between 9 to 12 months, n (%)

26 (2%)

7 (2%)

9 (2%)

6 (3%)

< 5

0 (0%)

< 5

Seen by a rheumatologist after 12 months, n (%)

68 (6%)

17 (5%)

25 (7%)

12 (7%)

10 (8%)

0 (0%)

< 5

Time from referral to first rheumatologist visit, Mean (SD), days

142 (332)

133 (345)

161 (377)

126 (257)

149 (284)

101 (60)

130 (308)

Time from referral to first rheumatologist visit, Median (IQR), days

61 (29-114)

47 (18-97)

70 (39-124)

56 (28-100)

69 (35-135)

112 (58-153)

58 (39-117)



Disclosure:

J. Widdifield,
None;

C. Bombardier,
None;

J. C. Thorne,
None;

R. L. Jaakkimainen,
None;

J. M. Paterson,
None;

S. Bernatsky,
None;

J. Young,
None;

L. Wing,
None;

N. Ivers,
None;

D. Butt,
None;

V. Poon,
None;

V. Ahluwalia,
None;

K. Tu,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-novel-approach-to-assess-wait-times-to-rheumatologists/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology